约搏以太坊博彩游戏www.eth108.vip)采用以太坊区块链高度哈希值作为统计数据,约搏以太坊博彩游戏数据开源、公平、无任何作弊可能性。

,“The gradual rise in consumer healthcare sales mix in the medium term will likely dilute the overall margins slightly, given the segment’s lower margin owing to its higher advertising and promotion costs,” CGS-CIMB Research said in its latest report.

KUALA LUMPUR: Pharmaniaga Bhd’s profit margins could see some pressures ahead on higher input costs.

The group noted in its recent briefing with *** ysts that higher input costs may potentially be felt from higher active pharmaceutical ingredient prices and the weaker ringgit to US dollar.

However, it said these factors have had a minimal impact so far on its margins, noting that this could change if the situation continues over the next three months or longer.

“The gradual rise in consumer healthcare sales mix in the medium term will likely dilute the overall margins slightly, given the segment’s lower margin owing to its higher advertising and promotion costs,” CGS-CIMB Research said in its latest report.

The research house has lowered its earnings before interest, taxes, depreciation and amortisation (Ebitda) margins forecast for Pharmaniaga slightly and expects Ebitda margin for the financial year 2022 (FY22) to contract by 3.3 percentage points to 4.6%.

“We believe our cuts sufficiently reflect the potential input cost pressures ahead,” it said.

Due to this, the research house had also cut its forecast core earnings per share for FY22-FY24 by 6% to 7.5% to factor in lower Ebitda margins and higher FY23-FY24 forecast capital expenditures for new warehouses.

CGS-CIMB Research had maintained its “add” rating on the stock but cut its target price to 73 sen, which is based on 15 times forecast price-to-earnings ratio for 2023.

Meanwhile, Pharmaniaga hopes to double or even triple its consumer healthcare revenue contribution by FY24 from a low base or less than 1% of revenue so far.

This would be supported by new product launches, which would help offset a normalisation in Vitamin C demand that was boosted by the Covid-19 surge prior to this.

“It is also exploring possible acquisitions of brands with established product ranges and customer base to expedite the consumer healthcare expansion and it has not factored this into its revenue target,” it added.

Pharmaniaga’s manufacturing plant for oral solid dosages in Bangi, Selangor, is operating at a utilisation rate of about 65%, which gives it room to ramp up output if the need arises.

“We believe the ample excess production capacity at Pharmaniaga’s existing plants will give it space for more output in the next three to five years on rising pharmaceutical demand and new product launches,” CGS-CIMB Research said.

Demand can be met with little to no incremental capital expenditures, it said.

电报群导航声明:该文看法仅代表作者自己,与本平台无关。转载请注明:约搏以太坊博彩游戏(www.eth108.vip)_Pressure on Pharmaniaga margins
发布评论

分享到:

欧博官网登录地址:Retailers see revenue from physical stores to rise
2 条回复
  1. 环球ug会员开户(www.ugbet.us)
    环球ug会员开户(www.ugbet.us)
    (2022-07-05 00:47:25) 1#

    东森衡宇2日在东森购物台,举行另具匠心的直播颁奖典礼,以线上直播方式,表彰去年度绩优房仲营业。东森衡宇是东森团体总裁王令麟第一个建立的事业,成立于民国77年,走店面不走楼面,并坚持不赚差价,去年营业额约三百亿,去年九月最先设立会员导客中央,将东森购物会员导向东森衡宇,预计今年营收增两成。我都看十遍了

  2. 新2会员手机管理端(www.hg9988.vip)
    新2会员手机管理端(www.hg9988.vip)
    (2022-08-11 21:40:55) 2#

    The land is accessible via Persiaran Eco Cascadia, it said in a statement yesterday.忒好看了点

发表评论

◎欢迎参与讨论,请在这里发表您的看法、交流您的观点。